OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Dimopoulos on BVd vs DVd in Relapsed/Refractory Multiple Myeloma With High-Risk Cytogenetic Features

August 27th 2025

Meletios A. Dimopoulos, MD, discusses the efficacy of BVd vs DVd in patients with relapsed or refractory multiple myeloma.

Dr Vento on the Clinical Significance of Somatic NGS in Guiding Treatment Decisions for Non–Clear Cell RCC

August 27th 2025

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Dr Hanna on the Pharmacokinetic Profile of Micvotabart Pelidotin in HNSCC

August 27th 2025

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and manageable safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

Dr Morgans on the Rationale for Evaluating Darolutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer

August 27th 2025

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

Dr Malhotra on Persisting Knowledge Gaps Surrounding the Use of ADCs in Lung Cancer

August 27th 2025

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Dr Nathan on the Rationale for Evaluating Roginolisib in Advanced Ocular or Uveal Melanoma

August 27th 2025

Paul Nathan, MBBS, PhD, MRCP, details the rationale for evaluating roginolisib in patients with advanced or metastatic ocular or uveal melanoma.

Dr Simpkins on the Clinical Applicability of Cyclin E1 Protein Expression as a Biomarker for Response to Azenosertib in Ovarian Cancer

August 26th 2025

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Dr Bedke on Advice for Using Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma

August 26th 2025

Jens Bedke, MD, discusses considerations for using enfortumab vedotin plus pembrolizumab in the frontline setting for advanced urothelial carcinoma.

Paulus on Research With a Real-World External Control Arm in HER2+ Breast Cancer

August 25th 2025

Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.

Dr Farolfi on Real-World Outcomes With Bevacizumab Plus SOC in Cervical Cancer

August 25th 2025

Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.

Dr Sarma on the Current Role of Sentinel Node Biopsies in Breast Cancer

August 25th 2025

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.

Dr Dorritie on the Management of Untreated and Relapsed/Refractory CLL

August 25th 2025

Kathleen A. Dorritie, MD, details the difference in care between the management of untreated CLL and relapsed/refractory CLL.

Dr McCann on the Importance of Integrating Patient Preferences Into Treatment Planning for Patients With HER2+ Breast Cancer

August 25th 2025

Kelly McCann, MD, PhD, discusses the relevance of patient preferences during treatment decision-making for patients with HER2-positive breast cancer.

Dr Wang on Evolving Challenges in the Management of CRPC

August 22nd 2025

Jue Wang, MD, discusses the evolving challenges in the management of castration-resistant prostate cancer.

Dr Cardoso on Outcomes With Elinzanetant for Hot Flashes in HR+ Breast Cancer

August 22nd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses quality-of-life outcomes with elinzanetant for the management of hot flashes in hormone receptor–positive breast cancer.

Dr Kremyanskaya on the Ongoing Development of Divesiran for Polycythemia Vera

August 22nd 2025

Marina Kremyanskaya, MD, PhD, discusses early-phase findings with divesiran in patients with polycythemia vera.

Dr Deng on the Role of MSH6 in Modulating PARP Inhibitor Sensitivity in BRCA-Proficient High-Grade Serous Ovarian Cancer

August 22nd 2025

Ou Deng, PhD, discusses research aimed at clarifying the role of MSH6 in modulating sensitivity to PARP inhibitors in patients with BRCA-proficient HGSOC

Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLC

August 22nd 2025

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Dr Lai on Post-Induction Treatment Strategies in mCRC

August 22nd 2025

Connie Lai, MD, discusses an analysis of post-induction maintenance vs treatment break in metastatic colorectal cancer.

Dr Dreyling on the Efficacy of Frontline Acalabrutinib Plus BR in High-Risk MCL

August 21st 2025

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.